This activity is supported by an independent education grant from Genmab. This online education program has been designed for healthcare professionals in the USA. The information in this program is not suitable for any other country.
Join expert Joshua Brody, MD, as he explores the rapidly evolving treatment landscape for relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). This session examines key clinical and logistical factors influencing treatment selection, compares the utility of bispecific antibodies with CAR-T and autologous transplant, and outlines approved and investigational CD20×CD3 bispecific agents.
This is Module One of Four. Modules Two, Three, and Four can be found here.
Session Highlights
- Navigating Clinical Complexity: Evaluating relapse kinetics, prior lines of therapy, comorbidities, and patient fitness to guide personalized therapy selection in R/R B-cell lymphomas.
- Comparing Cellular and Targeted Approaches: Weighing the distinct advantages, limitations, and logistical considerations of autologous transplant, CAR-T cell therapy, and bispecific antibodies.
- CD20×CD3 Mechanism of Action: Understanding how dual-affinity molecular designs bridge cytotoxic T-cells to malignant B-cells, triggering targeted antineoplastic activity.
- Bispecific Antibody Class Overview: Reviewing indications, dosing routes (IV vs. SC), and structural differences across glofitamab, epcoritamab, mosunetuzumab, and odronextamab.
Target Audience
This activity is intended for community-based healthcare professionals involved in the management and delivery of care for patients with R/R DLBCL and R/R FL, including community oncologists, community hematologists and hematology-oncologists, advanced practice providers (APPs), nurse practitioners, oncology nurses, pharmacists, and multidisciplinary care team members involved in treatment delivery and monitoring.
Faculty
Joshua Brody, MD - Director of the Lymphoma Immunotherapy Program at the Mount Sinai Tisch Cancer Center in New York City. Since joining Mount Sinai in 2011, he has developed a robust clinical program, as well as a translational Cancer Immunotherapy Lab which investigates basic and applied tumor immunology for the development of novel therapies, particularly for lymphomas, breast cancer, and head/neck cancer with results published in top-tier journals, including Nature Medicine and Cancer Discovery.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr Joshua Brody, faculty for this educational activity, has the following relevant financial relationships: Advisor for AbbVie, AstraZeneca, BeOne, Genmab, Janssen, Merck, Regeneron, and Roche/Genentech; Consultant for AbbVie, AstraZeneca, BeOne, Genmab, Janssen, Merck, Regeneron, and Roche/Genentech; Speaker for AbbVie, AstraZeneca, BeOne, Genmab, Janssen, Merck, Regeneron, and Roche/Genentech.
The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. Approval is valid until October 27, 2027. PAs should only claim credit commensurate with the extent of their participation.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.25 ANCC contact hours.
Pharmacy Continuing Education
Partners designates this continuing education activity for 0.25 contact hour(s) (0.025 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - TBA
Type of Activity: Application
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Instructions for Credit
Participation in this self-study activity should be completed in approximately 0.25 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from November 3, 2026 through to October 27, 2027.
- Review the objectives and disclosures
- Study the educational content
- Successfully complete activity post-test(s)
- Complete the activity evaluation
For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the online evaluation, your credit will be submitted to CPE Monitor. Please check your NABP account within thirty (30) days to make sure the credit has been posted.
This continuing education activity is active starting November 3, 2026 and will expire on October 27, 2027.
Estimated time to complete this activity: 15 Minutes